首页> Journal of nuclear medicine : official publication, Society of Nuclear Medicine> Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle.

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle.

导出原文传递

翻译打印收藏纠错

第一作者： Kristina,Westerlund

第一单位： Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.

作者： Kristina,Westerlund ^[1] ; Mohamed,Altai ^[2] ; Bogdan,Mitran ^[3] ; Mark,Konijnenberg ^[4] ; Maryam,Oroujeni ^[2] ; Christina,Atterby ^[2] ; Marion,de Jong ^[4] ; Anna,Orlova ^[3] ; Johanna,Mattsson ^[2] ; Patrick,Micke ^[2] ; Amelie Eriksson,Karlström ^[1] ; Vladimir,Tolmachev ^[5]

作者单位： Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden. ^[1] Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. ^[2] Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and. ^[3] Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. ^[4] Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden vladimir.tolmachev@igp.uu.se. ^[5]

关键词 HER2 PNA affibody molecules pretargeting radionuclide therapy